Opendata, web and dolomites

MaxONCO SIGNED

A cancer vaccine to boost body’s natural defences to fight chordoma and head and neck cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MaxONCO project word cloud

Explore the words cloud of the MaxONCO project. It provides you a very rough idea of what is the project "MaxONCO" about.

situ    fast    650    acting    company    initial    survived    care    treatment    point    switzerland    line    base    biotech    chordoma    grow    stage    clinical    prepare    ind    opportunity    spine    drug    drugs    first    benefit    sites    trials    immune    limited    diagnosed    indirect    swissmedic    2018    released    commercialization    autologous    occurs    cancer    antigens    radiotherapy    surgery    time    source    develops    maxivax    types    accounting    market    employees    sme    besides    neck    salivary    compare    modified    patients    orphan    vaccine    swiss    plans    benign    cell    showed    standard    positive    shown    initiated    data    biological    throat    immuno    encouraging    therapy    anywhere    agent    primary    boost    group    cells    approval    treat    immunotherapy    globally    efficacy    maxonco    mouth    glands    rare    45    rate    jobs    skull    approved    showing    cancers    25    indications    fda    genetically    head    usa    indication    designation    safety    perform    breakthrough    profile    track    trial    investigational    private   

Project "MaxONCO" data sheet

The following table provides information about the project.

Coordinator
MAXIVAX SA 

Organization address
address: RUE DE LATHEENEE 24
city: GENEVA
postcode: 1206
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 3˙979˙000 €
 EC max contribution 2˙785˙300 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAXIVAX SA CH (GENEVA) coordinator 2˙785˙300.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

MaxiVAX a private Swiss clinical-stage biotech company with a novel cancer immunotherapy product in development (MaxONCO) will perform two Phase 2 clinical trials in two indications (Head & Neck, and Chordoma) and prepare the commercialization of MaxONCO, its first immuno-therapy product. The objective of the Phase II clinical trials is to demonstrate efficacy and safety of MaxONCO in the patients treated and compare the results to the current standard of care. MaxONCO is a biological product acting as a cancer vaccine and composed of (i) an immune boost agent released in situ by a genetically modified cell line and (ii) cancer autologous cells, which are the source of antigens. A Phase 1 trial in 25 patients with a range of cancer types at an advanced stage showed encouraging efficacy data and a benign safety profile of the treatment. Head and Neck cancer is a group of cancers that develops in the areas of the head and neck which include the mouth, throat and salivary glands; accounting for 650,000 new cases in 2018 diagnosed globally. With the approval of Swissmedic, MaxiVAX has initiated the Phase 2 clinical trial to evaluate MaxONCO in 40-45 patients with Head & Neck cancer. The study will be conducted across 4-6 different sites in Switzerland. Encouraging clinical results show that among 4 initial Head & Neck patients treated with MaxONCO all survived beyond the 6-month time point (primary efficacy end point). Chordoma is a rare type of cancer that occurs in the skull base and anywhere along the spine. Besides surgery and radiotherapy that are showing only limited success, there are currently no approved drugs to treat Chordoma. In the Phase 1 clinical trial, MaxONCO, has shown promising effects on chordoma patients. A phase 2 Chordoma clinical trial will be conducted in the EU and USA, under an FDA investigational new drug application (IND). A positive overall response rate in Chordoma would allow MaxONCO to benefit from the breakthrough therapy designation as fast-track market opportunity, Chordoma being an orphan indication. Currently accounting for 8 employees, the company plans to grow up to 25 employees by the end of the SME phase 2 project, creating up to 30 indirect jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAXONCO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAXONCO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More